{"id":"NCT01411228","sponsor":"Pfizer","briefTitle":"A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","officialTitle":"A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2014-07","completion":"2014-08","firstPosted":"2011-08-08","resultsPosted":"2016-01-18","lastUpdate":"2018-09-07"},"enrollment":15,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease"],"interventions":[{"type":"DRUG","name":"Taliglucerase alfa","otherNames":["prGCD, plant cell expressed glucocerebrosidase"]}],"arms":[{"label":"60 Units/kg","type":"EXPERIMENTAL"},{"label":"30 Units/kg","type":"EXPERIMENTAL"}],"summary":"A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to \\<18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (naÃ¯ve treatment with taliglucerase alfa).","primaryOutcome":{"measure":"Hemoglobin","timeFrame":"Baseline, months 9, 12 and 24","effectByArm":[{"arm":"60 Units/kg","deltaMin":10.6,"sd":null},{"arm":"30 Units/kg","deltaMin":11.2,"sd":null},{"arm":"Switchover","deltaMin":13.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":3,"countries":["Israel","Paraguay","South Africa"]},"refs":{"pmids":["27839981","26053270"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":5},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","COUGH","LYMPHADENOPATHY","ABDOMINAL PAIN"]}}